EGFR and neoplasm: These findings may be attributed to a proportion of mutated cells transforming into refractory clones through various mechanisms while acquiring resistance after first‐generation EGFR‐TKI treatment, whereas other tumor cells might remain reliant on the EGFR pathway at the molecular level.